孟鲁司特钠治疗慢性咳嗽小气道病变的临床疗效观察

Observation of clinical effect of montelukast sodium in the treatment of chronic cough with small airway disease

目的 探讨孟鲁司特钠治疗慢性咳嗽小气道病变的临床疗效.方法 选取50例慢性咳嗽小气道病变患者,采用随机数字表法分为孟鲁司特钠组和对照组,每组25例.对照组患者给予常规治疗,孟鲁司特钠组患者在常规治疗的基础上给予孟鲁司特钠治疗.治疗结束后,比较两组患者的临床效果.结果 孟鲁司特钠组的总有效率为92.0％,对照组为84.0％,两组差异无统计学意义（x^2 =1.05,P＞0.05）.治疗3个月,两组肺功能均有改善,与对照组比较,孟鲁司特钠组的第一秒用力呼气容积（FEV1）、用力肺活量（FVC）、1秒率（FEV1/FVC％）差异均无统计学意义（t=0.71、0.64、1.46,均P＞0.05）,呼气中期流速（FEF25％～75％）、呼气中期瞬间流速（FEF50％）、呼气后期瞬间流速（FEF75％）明显改善,差异均有统计学意义（t=7.07、2.62、3.83,均P＜0.01）.治疗6个月,两组FEF75％差异有统计学意义（t=1.92,P＜0.05）.孟鲁司特钠组的血清IgE水平明显降低,两组差异有统计学意义（t=4.02,P＜0.01）.两组均未出现严重的不良反应,差异无统计学意义（x^2=1.42,P＞0.05）.结论 孟鲁司特钠治疗慢性咳嗽小气道病变疗效显著,有利于改善小气道病变,降低血清IgE水平,安全有效,值得临床推广应用.

Objective To explore the clinical efficacy of montelukast sodium in the treatment of chronic cough with small airway disease.Methods 50 chronic cough patients with small airway disease were selected,and they were randomly divided into montelukast sodium group and control group according to the digital table,25 cases in each group.The control group was given conventional treatment,the montelukast sodium group was treated with montelukast sodium on the basis of routine treatment.At the end of treatment,the clinical effect of the two groups was compared.Results The total effective rate of the montelukast sodium group was 92.0%,which of the control group was 84.0%,the difference was not statistically significant between the two groups （x^2 =1.05,P 〉 0.05）.After 3 months of treatment,the pulmonary function of the two groups was significantly improved.Compared with the control group,the FEV1,FVC and FEV1/FVC% of the montelukast sodium group showed no statistically significant differences（t =0.71,0.64,1.46,all P 〉 0.05）,but the FEF25 %-75 %,FEF50%,FEF75 % improved significantly with significant differences （t =7.07,2.62,3.83,all P 〈 0.01）.After 6 months of treatment,the difference of FEF75 % was statistically significant between the two groups （t =1.92,P 〈 0.05）.Compared with the control group,the level of serum IgE was significantlylower in the montelukast sodium group（t =4.02,P 〈0.01）.There were no serious adverse reactions in the two groups,the difference was not statistically significant （x^2 =1.42,P 〉 0.05）.Conclusion Montelukast sodium in the treatment of chronic cough with small airway disease has significant effcet,it is conducive to improve small airway disease and reduce serum IgE level,it is safe,effective and worthy of clinical application.